Protective effect of resveratrol against pembrolizumab‐induced hepatotoxicity and neurotoxicity in male rats

The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity. Obtained for the study were 28 male Sprague‐Dawley rats (3–4 months old) which were divided into four groups: Group 1: Control. Group 2: Administered PEMB at...

Full description

Saved in:
Bibliographic Details
Published inJournal of biochemical and molecular toxicology Vol. 37; no. 3; pp. e23263 - n/a
Main Authors Türkmen, Neşe B., Yüce, Hande, Şahin, Yasemin, Taşlıdere, Aslı Ç., Özek, Dilan A., Ünüvar, Songül, Çiftçi, Osman
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity. Obtained for the study were 28 male Sprague‐Dawley rats (3–4 months old) which were divided into four groups: Group 1: Control. Group 2: Administered PEMB at 5 mg/kg/day i.p. for a week. Group 3: Administered RSV orally at the dose of 20 mg/kg/day for 30 days by gavage. Group 4: Administered PEMB and RSV at 20 and 5 mg/kg/day RSV, respectively, for 30 days. The results of this study revealed that PEMB leads to a significant increase in thiobarbituric acid reactive substance (TBARS) levels and a significant decrease in glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) activities, and glutathione (GSH) levels in the liver and brain tissues. The decreased SOD, CAT, GPx activities, and GSH levels increased significantly following RSV treatment in Group 4. The PEMB treatment showed histopathological alterations associated with strong positive cysteinyl aspartic acid‐protease‐3 (caspase‐3) immunoreactivity, while RSV treatment reduced both the expression of caspase‐3 protein and the histopathological changes. RSV administration prevents the biochemical, immunological, and histological alterations induced by PEMB. It can be suggested that the lower caspase‐3 immunoreactivity in the PEMB + RSV group than in the PEMB group led to an inhibition of RSV on apoptosis.
AbstractList The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity. Obtained for the study were 28 male Sprague‐Dawley rats (3–4 months old) which were divided into four groups: Group 1: Control. Group 2: Administered PEMB at 5 mg/kg/day i.p. for a week. Group 3: Administered RSV orally at the dose of 20 mg/kg/day for 30 days by gavage. Group 4: Administered PEMB and RSV at 20 and 5 mg/kg/day RSV, respectively, for 30 days. The results of this study revealed that PEMB leads to a significant increase in thiobarbituric acid reactive substance (TBARS) levels and a significant decrease in glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) activities, and glutathione (GSH) levels in the liver and brain tissues. The decreased SOD, CAT, GPx activities, and GSH levels increased significantly following RSV treatment in Group 4. The PEMB treatment showed histopathological alterations associated with strong positive cysteinyl aspartic acid‐protease‐3 (caspase‐3) immunoreactivity, while RSV treatment reduced both the expression of caspase‐3 protein and the histopathological changes. RSV administration prevents the biochemical, immunological, and histological alterations induced by PEMB. It can be suggested that the lower caspase‐3 immunoreactivity in the PEMB + RSV group than in the PEMB group led to an inhibition of RSV on apoptosis.
The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity. Obtained for the study were 28 male Sprague‐Dawley rats (3–4 months old) which were divided into four groups: Group 1: Control. Group 2: Administered PEMB at 5 mg/kg/day i.p. for a week. Group 3: Administered RSV orally at the dose of 20 mg/kg/day for 30 days by gavage. Group 4: Administered PEMB and RSV at 20 and 5 mg/kg/day RSV, respectively, for 30 days. The results of this study revealed that PEMB leads to a significant increase in thiobarbituric acid reactive substance (TBARS) levels and a significant decrease in glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) activities, and glutathione (GSH) levels in the liver and brain tissues. The decreased SOD, CAT, GPx activities, and GSH levels increased significantly following RSV treatment in Group 4. The PEMB treatment showed histopathological alterations associated with strong positive cysteinyl aspartic acid‐protease‐3 (caspase‐3) immunoreactivity, while RSV treatment reduced both the expression of caspase‐3 protein and the histopathological changes. RSV administration prevents the biochemical, immunological, and histological alterations induced by PEMB. It can be suggested that the lower caspase‐3 immunoreactivity in the PEMB + RSV group than in the PEMB group led to an inhibition of RSV on apoptosis.
Abstract The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity. Obtained for the study were 28 male Sprague‐Dawley rats (3–4 months old) which were divided into four groups: Group 1: Control. Group 2: Administered PEMB at 5 mg/kg/day i.p. for a week. Group 3: Administered RSV orally at the dose of 20 mg/kg/day for 30 days by gavage. Group 4: Administered PEMB and RSV at 20 and 5 mg/kg/day RSV, respectively, for 30 days. The results of this study revealed that PEMB leads to a significant increase in thiobarbituric acid reactive substance (TBARS) levels and a significant decrease in glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) activities, and glutathione (GSH) levels in the liver and brain tissues. The decreased SOD, CAT, GPx activities, and GSH levels increased significantly following RSV treatment in Group 4. The PEMB treatment showed histopathological alterations associated with strong positive cysteinyl aspartic acid‐protease‐3 (caspase‐3) immunoreactivity, while RSV treatment reduced both the expression of caspase‐3 protein and the histopathological changes. RSV administration prevents the biochemical, immunological, and histological alterations induced by PEMB. It can be suggested that the lower caspase‐3 immunoreactivity in the PEMB + RSV group than in the PEMB group led to an inhibition of RSV on apoptosis.
Author Türkmen, Neşe B.
Yüce, Hande
Özek, Dilan A.
Çiftçi, Osman
Taşlıdere, Aslı Ç.
Şahin, Yasemin
Ünüvar, Songül
Author_xml – sequence: 1
  givenname: Neşe B.
  orcidid: 0000-0001-5566-8321
  surname: Türkmen
  fullname: Türkmen, Neşe B.
  organization: Inonu University
– sequence: 2
  givenname: Hande
  orcidid: 0000-0003-2907-2019
  surname: Yüce
  fullname: Yüce, Hande
  organization: Inonu University
– sequence: 3
  givenname: Yasemin
  orcidid: 0000-0003-4226-674X
  surname: Şahin
  fullname: Şahin, Yasemin
  organization: Pamukkale University
– sequence: 4
  givenname: Aslı Ç.
  orcidid: 0000-0003-3902-3210
  surname: Taşlıdere
  fullname: Taşlıdere, Aslı Ç.
  organization: Inonu University
– sequence: 5
  givenname: Dilan A.
  orcidid: 0000-0001-9075-4807
  surname: Özek
  fullname: Özek, Dilan A.
  organization: Firat University
– sequence: 6
  givenname: Songül
  orcidid: 0000-0001-8454-490X
  surname: Ünüvar
  fullname: Ünüvar, Songül
  email: songul.unuvar@inonu.edu.tr
  organization: Inonu University
– sequence: 7
  givenname: Osman
  orcidid: 0000-0001-5755-3560
  surname: Çiftçi
  fullname: Çiftçi, Osman
  organization: Pamukkale University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36419233$$D View this record in MEDLINE/PubMed
BookMark eNp1kMtO3DAUhq0KVGDaRV-gstQVi4AvsZMsKeqFCoku6Do6To5bjyb2YDvQYdVH6DP2STAMhRWbc9On70j_AdnxwSMh7zg74oyJ46XJR0IKLV-Rfc66rmK15jsPs6q0btgeOUhpyRhTXaNekz2pa94JKfeJ_x5DxiG7a6RobZlosDRiusYIOYYVhZ_gfMp0jZMpu7udJzD__vx1fpwHHOkvXEMOOfx2g8sbCn6kHuf4fHGeTrBCWnzpDdm1sEr49rEvyI_Pny5Pv1bnF1_OTk_Oq0EqKSsuzGDHUTMDTQ2tbMdBAXS6rpUeGYNSUHcMBDcKWys4WCGYNo3sGmiNlQvyYetdx3A1Y8r9MszRl5e9aFrF21qVPwtyuKWGGFKKaPt1dBPETc9Zf59sX5LtH5It7PtH42wmHJ_I_1EW4HgL3LgVbl429d8-Xm6Vd9vLh7A
CitedBy_id crossref_primary_10_3390_nu16132141
Cites_doi 10.1111/apt.15413
10.1093/clinchem/34.3.497
10.1016/S0021-9258(19)52451-6
10.1016/0003-2697(68)90092-4
10.1080/01926230701320337
10.1080/15569527.2017.1361438
10.1093/gastro/goz044
10.1007/s11010-019-03582-z
10.1016/j.neuint.2021.105188
10.1038/nrc.2016.36
10.1080/10408398.2016.1263597
10.1016/S0140-6736(13)62224-2
10.1053/j.semdp.2019.07.009
10.2169/internalmedicine.2591-18
10.1159/000518128
10.1042/BST0351156
10.3390/cancers13184509
10.1172/JCI80011
10.3892/br.2016.777
10.1136/bmj.k793
10.29252/ijrm.16.3.149
10.1111/liv.13746
10.1016/j.ajem.2018.10.040
10.1093/annonc/mdv383
10.1016/j.febslet.2013.10.015
10.1016/j.ejca.2016.02.024
10.1016/S1470-2045(20)30111-X
10.1038/nm0303-269
10.3390/brainsci12060773
10.1016/j.critrevonc.2017.04.011
10.1016/S1470-2045(16)30053-5
10.2174/1567205016666190801153751
10.1007/s00210-018-1495-3
10.1186/s40425-015-0078-9
10.1038/s41523-021-00267-z
10.1186/2051-1426-3-S2-P415
ContentType Journal Article
Copyright 2022 Wiley Periodicals LLC.
2023 Wiley Periodicals LLC.
Copyright_xml – notice: 2022 Wiley Periodicals LLC.
– notice: 2023 Wiley Periodicals LLC.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7U7
8FD
C1K
FR3
K9.
P64
DOI 10.1002/jbt.23263
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Biotechnology Research Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList
Biotechnology Research Abstracts
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Biology
EISSN 1099-0461
EndPage n/a
ExternalDocumentID 10_1002_jbt_23263
36419233
JBT23263
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OC
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACIWK
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F3I
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HF~
HGLYW
HHY
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SUPJJ
SV3
UB1
V2E
W8V
W99
WBFHL
WBKPD
WIH
WIK
WJL
WOHZO
WQJ
WRC
WXSBR
WYISQ
XG1
XPP
XV2
ZZTAW
~IA
~WT
ACXME
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7U7
8FD
C1K
FR3
K9.
P64
ID FETCH-LOGICAL-c3533-12bcfdd60ba74a838dc5aa964456d00a6d0e690a21b5e8f21af2206b7397a8bf3
IEDL.DBID DR2
ISSN 1095-6670
IngestDate Fri Sep 13 06:04:53 EDT 2024
Fri Aug 23 00:25:54 EDT 2024
Thu May 23 23:32:20 EDT 2024
Sat Aug 24 01:07:08 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords pembrolizumab
neurotoxicity
resveratrol
hepatotoxicity
oxidative stress
Language English
License 2022 Wiley Periodicals LLC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3533-12bcfdd60ba74a838dc5aa964456d00a6d0e690a21b5e8f21af2206b7397a8bf3
ORCID 0000-0001-9075-4807
0000-0003-3902-3210
0000-0003-2907-2019
0000-0003-4226-674X
0000-0001-8454-490X
0000-0001-5566-8321
0000-0001-5755-3560
PMID 36419233
PQID 2785184553
PQPubID 1006378
PageCount 10
ParticipantIDs proquest_journals_2785184553
crossref_primary_10_1002_jbt_23263
pubmed_primary_36419233
wiley_primary_10_1002_jbt_23263_JBT23263
PublicationCentury 2000
PublicationDate March 2023
2023-Mar
2023-03-00
20230301
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: March 2023
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of biochemical and molecular toxicology
PublicationTitleAlternate J Biochem Mol Toxicol
PublicationYear 2023
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 1968; 25
2019; 8
2021; 7
2018; 360
2015; 3
2019; 50
2015; 125
2019; 37
2019; 58
2019; 36
2019; 16
1988; 34
2019; 460
2016; 17
2016; 16
2017; 115
2007; 35
2016; 5
2021; 13
2015; 26
1967; 70
2021; 15
2018; 391
2016; 2
2013; 12
2003; 9
1998; 108
1951; 193
2022; 12
2021; 150
1984
2016; 60
2020; 21
2014; 383
2018; 16
2018; 38
2018; 37
2014; 588
2018; 58
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_33_1
Paglia D. E. (e_1_2_9_21_1) 1967; 70
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
Valsan A. (e_1_2_9_12_1) 2016; 2
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_18_1
e_1_2_9_42_1
e_1_2_9_20_1
e_1_2_9_40_1
e_1_2_9_22_1
Mokni M. (e_1_2_9_41_1) 2013; 12
Yagi K. (e_1_2_9_17_1) 1998; 108
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
Aebi H. (e_1_2_9_19_1) 1984
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 9
  issue: 3
  year: 2003
  publication-title: Nat. Med.
– volume: 108
  start-page: 101
  year: 1998
  publication-title: Methods Mol. Biol.
– volume: 17
  start-page: 976
  year: 2016
  publication-title: Lancet Oncol.
– volume: 37
  start-page: 376.e1
  issue: 376
  year: 2019
  publication-title: Am. J. Emerg. Med.
– volume: 13
  issue: 18
  year: 2021
  publication-title: Cancers
– volume: 26
  start-page: 2375
  year: 2015
  publication-title: Ann. Oncol.
– volume: 7
  start-page: 59
  year: 2021
  publication-title: NPJ Breast Cancer
– volume: 25
  start-page: 192
  issue: 1
  year: 1968
  publication-title: Anal. Biochem.
– volume: 588
  start-page: 368
  year: 2014
  publication-title: FEBS Lett.
– volume: 150
  year: 2021
  publication-title: Neurochem. Int.
– volume: 35
  start-page: 495
  year: 2007
  publication-title: Toxicol. Pathol.
– volume: 460
  start-page: 217
  year: 2019
  publication-title: Mol. Cell. Biochem.
– volume: 34
  issue: 3
  year: 1988
  publication-title: Clin. Chem.
– volume: 70
  start-page: 158
  issue: 1
  year: 1967
  publication-title: J. Lab. Clin. Med.
– volume: 37
  start-page: 151
  year: 2018
  publication-title: Cutaneous Ocul. Toxicol.
– volume: 58
  start-page: 1428
  year: 2018
  publication-title: Crit. Rev. Food Sci. Nutr.
– volume: 193
  start-page: 265
  year: 1951
  publication-title: J. Biol. Chem.
– volume: 21
  start-page: 655
  year: 2020
  publication-title: Lancet Oncol.
– volume: 2
  start-page: 75
  year: 2016
  publication-title: South Ind. J. Biol. Sci.
– volume: 3
  start-page: 36
  year: 2015
  publication-title: J. Immunother. Cancer
– volume: 16
  year: 2018
  publication-title: Int. J. Reprod. Biomed.
– volume: 391
  start-page: 783
  year: 2018
  publication-title: Naunyn‐Schmiedeberg's Arch. Pharmacol.
– volume: 38
  start-page: 976
  year: 2018
  publication-title: Liver Int.
– volume: 50
  start-page: 800
  year: 2019
  publication-title: Aliment. Pharmacol. Ther.
– volume: 360
  year: 2018
  publication-title: BMJ
– volume: 8
  start-page: 50
  year: 2019
  publication-title: Gastroenterol. Rep.
– volume: 35
  year: 2007
  publication-title: Biochem. Soc. Trans.
– volume: 115
  start-page: 50
  year: 2017
  publication-title: Crit. Rev. Oncol. Hematol.
– volume: 3
  issue: 2
  year: 2015
  publication-title: J. Immunother. Cancer
– volume: 58
  start-page: 3283
  year: 2019
  publication-title: Intern. Med.
– volume: 16
  start-page: 710
  year: 2019
  publication-title: Curr. Alzheimer Res.
– volume: 125
  start-page: 3384
  year: 2015
  publication-title: J. Clin. Invest.
– start-page: 121
  year: 1984
– volume: 60
  start-page: 210
  year: 2016
  publication-title: Eur. J. Cancer
– volume: 383
  start-page: 549
  year: 2014
  publication-title: Lancet
– volume: 12
  issue: 6
  year: 2022
  publication-title: Brain Sci.
– volume: 5
  start-page: 525
  year: 2016
  publication-title: Biomed. Rep.
– volume: 12
  start-page: 867
  year: 2013
  publication-title: Iran. J. Pharm. Res.
– volume: 36
  start-page: 434
  issue: 6
  year: 2019
  publication-title: Semin. Diagn. Pathol.
– volume: 15
  start-page: 742
  issue: 2
  year: 2021
  publication-title: Case Rep. Gastroenterol.
– volume: 16
  start-page: 275
  year: 2016
  publication-title: Nat. Rev. Cancer
– volume: 2
  start-page: 75
  year: 2016
  ident: e_1_2_9_12_1
  publication-title: South Ind. J. Biol. Sci.
  contributor:
    fullname: Valsan A.
– ident: e_1_2_9_29_1
  doi: 10.1111/apt.15413
– ident: e_1_2_9_18_1
  doi: 10.1093/clinchem/34.3.497
– ident: e_1_2_9_22_1
  doi: 10.1016/S0021-9258(19)52451-6
– ident: e_1_2_9_20_1
  doi: 10.1016/0003-2697(68)90092-4
– ident: e_1_2_9_38_1
  doi: 10.1080/01926230701320337
– ident: e_1_2_9_24_1
  doi: 10.1080/15569527.2017.1361438
– ident: e_1_2_9_30_1
  doi: 10.1093/gastro/goz044
– ident: e_1_2_9_16_1
  doi: 10.1007/s11010-019-03582-z
– ident: e_1_2_9_14_1
  doi: 10.1016/j.neuint.2021.105188
– ident: e_1_2_9_25_1
  doi: 10.1038/nrc.2016.36
– ident: e_1_2_9_40_1
  doi: 10.1080/10408398.2016.1263597
– ident: e_1_2_9_2_1
  doi: 10.1016/S0140-6736(13)62224-2
– ident: e_1_2_9_32_1
  doi: 10.1053/j.semdp.2019.07.009
– ident: e_1_2_9_31_1
  doi: 10.2169/internalmedicine.2591-18
– ident: e_1_2_9_33_1
  doi: 10.1159/000518128
– ident: e_1_2_9_11_1
  doi: 10.1042/BST0351156
– volume: 70
  start-page: 158
  issue: 1
  year: 1967
  ident: e_1_2_9_21_1
  publication-title: J. Lab. Clin. Med.
  contributor:
    fullname: Paglia D. E.
– ident: e_1_2_9_42_1
  doi: 10.3390/cancers13184509
– ident: e_1_2_9_3_1
  doi: 10.1172/JCI80011
– ident: e_1_2_9_10_1
  doi: 10.3892/br.2016.777
– ident: e_1_2_9_7_1
  doi: 10.1136/bmj.k793
– ident: e_1_2_9_15_1
  doi: 10.29252/ijrm.16.3.149
– ident: e_1_2_9_28_1
  doi: 10.1111/liv.13746
– ident: e_1_2_9_9_1
  doi: 10.1016/j.ajem.2018.10.040
– ident: e_1_2_9_8_1
  doi: 10.1093/annonc/mdv383
– ident: e_1_2_9_26_1
  doi: 10.1016/j.febslet.2013.10.015
– ident: e_1_2_9_36_1
  doi: 10.1016/j.ejca.2016.02.024
– ident: e_1_2_9_34_1
  doi: 10.1016/S1470-2045(20)30111-X
– volume: 12
  start-page: 867
  year: 2013
  ident: e_1_2_9_41_1
  publication-title: Iran. J. Pharm. Res.
  contributor:
    fullname: Mokni M.
– ident: e_1_2_9_5_1
  doi: 10.1038/nm0303-269
– ident: e_1_2_9_37_1
  doi: 10.3390/brainsci12060773
– start-page: 121
  volume-title: Methods in Enzymology
  year: 1984
  ident: e_1_2_9_19_1
  contributor:
    fullname: Aebi H.
– ident: e_1_2_9_6_1
  doi: 10.1016/j.critrevonc.2017.04.011
– ident: e_1_2_9_35_1
  doi: 10.1016/S1470-2045(16)30053-5
– ident: e_1_2_9_13_1
  doi: 10.2174/1567205016666190801153751
– ident: e_1_2_9_23_1
  doi: 10.1007/s00210-018-1495-3
– volume: 108
  start-page: 101
  year: 1998
  ident: e_1_2_9_17_1
  publication-title: Methods Mol. Biol.
  contributor:
    fullname: Yagi K.
– ident: e_1_2_9_27_1
  doi: 10.1186/s40425-015-0078-9
– ident: e_1_2_9_39_1
  doi: 10.1038/s41523-021-00267-z
– ident: e_1_2_9_4_1
  doi: 10.1186/2051-1426-3-S2-P415
SSID ssj0005975
Score 2.3692524
Snippet The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity. Obtained for the...
The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)-induced toxicity. Obtained for the...
Abstract The present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)‐induced toxicity....
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage e23263
SubjectTerms Animal tissues
Animals
Antioxidants - pharmacology
Apoptosis
Aspartic acid
Brain
Caspase
Caspase 3 - metabolism
Catalase
Catalase - metabolism
Chemical and Drug Induced Liver Injury - metabolism
Glutathione
Glutathione - metabolism
Glutathione peroxidase
Glutathione Peroxidase - metabolism
Hepatotoxicity
Immunology
Immunoreactivity
Liver
Liver - metabolism
Male
Males
Neurotoxicity
Oxidative Stress
Pembrolizumab
Peroxidase
Rats
Rats, Sprague-Dawley
Resveratrol
Resveratrol - pharmacology
Superoxide dismutase
Superoxide Dismutase - metabolism
Thiobarbituric acid
Toxicity
Title Protective effect of resveratrol against pembrolizumab‐induced hepatotoxicity and neurotoxicity in male rats
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjbt.23263
https://www.ncbi.nlm.nih.gov/pubmed/36419233
https://www.proquest.com/docview/2785184553/abstract/
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3datswFMdFKBQKpV2zdW3XDTF6sRuntmwpCrvaRkMotIySQC8G5ujDW9bGDolTtl71EfaMe5IdWbFDVgajN8ZYtrB9JJ2fvv6HkBOpexz9vA0MSB4kFkSgDISBRl_MElDYKLoZ3YtLMRgl59f8ukXe13thvD5EM-DmakbVXrsKDmp-uhIN_a7KDuKAcEqfTkjPAdHVSjoKQZlXM509HgjRDWtVoZCdNk-u-6JHgLnOq5XD6e-SL_Wr-nUmN51FqTr6_i8Vxyd-yzOyswRR-sGXnD3SsnmbbPrQlD_bZNuP51G_Tek5yT97QQdsHKlfA0KLjGJf_c6pMs-KWwpfYYysSad2olwooPvFBNTvh1_Y6cfiY-g3dHxlURY_xhrJn0JuaCWm2VwZ53SC7opifvMXZNQ_G34aBMtYDWhVJMYgYkpnxohQQTcBGUujOUAPaYsLE4aAB4sdcWCR4lZmLIKMsVCoLvIQSJXF-2QjL3J7QKiOJLYMoVYa0UNzqWQCYCG2wGSUmeiQvK2tlk69JEfqxZdZij8yrX7kITmu7Zkua-U8ZV3kS5lwjskvvY2bHGLh5sNjTHlXWerfWafnH4fVydH_3_qKbLk49X7x2jHZKGcL-xppplRvqmL7B6hf8p4
link.rule.ids 315,786,790,1382,27957,27958,46329,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61RahIiEfpi7ZgIQ5csps4sdcrcaGIailthdBW6gVF40faBTap2iyCnvoT-hv5JUzszVYtQkJcoihOLMfjmfnGj28AXirTF-TnXWRRiShzKCNtMY4M-WKeoSaj2Kzo7h_IwWG2eySO5uB1exYm8EPMJtwazfD2ulHwZkK6e80a-kXXHcIDMp2HO6TuwgdUn67JowgqC7_W2ReRlL245RWKeXf26U1v9AfEvIlYvcvZeQif28aGnSZfO5Nad8zFLR7H__2bR_BgikXZmzB4HsOcK5fgbshO-XMJ7ocpPRZOKj2B8mPgdCD7yMI2EFYVjML17w0x81n1jeExjghuslM31k02oIvJGPWvyyuK-2kEWXZCvq-u6urHyBD4Z1ha5vk0Z09GJRuTx2JU3_kyHO68G74dRNN0DSRYAo1RwrUprJWxxl6GKlXWCMQ-AS4hbRwjXRzF4sgTLZwqeIIF57HUPYJEqHSRrsBCWZVuDZhJFBmH2GhD6MMIpVWG6DB1yFVS2GQdXrRiy08DK0ce-Jd5Th2Z-45ch81WoPlUMc9z3iOIqTIhqHg1CHlWQyqbJfGUSl55Uf296nx3e-hvnv77q89hcTDc38v33h982IB7Tdr6sJdtExbqs4nbInBT62d-DP8G2C_2wA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEB_UUhGKtdZarW0X6UNfciab7N4ePrW1h9-IKPhQCLMfqdd6yaE5UZ_8E_wb-5d0kr2caCmUvoSQTZbNzuzMb_bjNwAflOkI8vMusKhEkDiUgbYYBoZ8MU9Qk1GsVnT39uXmcbJ9Ik4mYL05C-P5IcYTbtXIqO11NcAHNlu7Jw39ocsWwQEZT8KTRMa8UumNw3vuKELKol7q7IhAynbY0AqFfG386UNn9AfCfAhYa4_TfQ7fmrb6jSY_W8NSt8zNIxrH__yZOZgdIVH2yavOC5hw-Tw89bkpr-fhmZ_QY_6c0kvIDzyjA1lH5jeBsCJjFKxfVrTM58UZw-_YI7DJBq6vq1xAN8M-6l-3dxT1k_5YdkqeryzK4qpnCPozzC2r2TTHT3o565O_YlTfxQIcd78efdkMRskaSKwEGYOIa5NZK0ON7QRVrKwRiB2CW0LaMES6OIrEkUdaOJXxCDPOQ6nbBIhQ6Sx-BVN5kbvXwEykyDSERhvCHkYorRJEh7FDrqLMRkuw2kgtHXhOjtSzL_OUOjKtO3IJVhp5pqNheZHyNgFMlQhBxYtexuMaYlktiMdU8rGW1N-rTrc_H9U3y__-6nuYPtjoprtb-ztvYKbKWe83sq3AVHk-dG8J2ZT6Xa3BvwEI3vVv
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+effect+of+resveratrol+against+pembrolizumab%E2%80%90induced+hepatotoxicity+and+neurotoxicity+in+male+rats&rft.jtitle=Journal+of+biochemical+and+molecular+toxicology&rft.au=T%C3%BCrkmen%2C+Ne%C5%9Fe+B&rft.au=Y%C3%BCce%2C+Hande&rft.au=%C5%9Eahin%2C+Yasemin&rft.au=Ta%C5%9Fl%C4%B1dere%2C+Asl%C4%B1+%C3%87&rft.date=2023-03-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1095-6670&rft.eissn=1099-0461&rft.volume=37&rft.issue=3&rft_id=info:doi/10.1002%2Fjbt.23263&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1095-6670&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1095-6670&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1095-6670&client=summon